The Urology Surgery department of Zhongshan Hospital was founded in 1952 and it was one of the first to establish urology department in China, with70 beds and an independent ward at that time. The first director of the department, Professor Xiong Rucheng, is one of the pioneers of urology surgery in China. The following directors are Professor Zhang Ren’an, Zhang Yuanfang, Zhang Yongkang and Wang Guomin. The current director is Chief Physician Guo Jianming. With the guidance of several generations of urology experts over the past six decades, the urology surgery department at Zhongshan Hospital has made remarkable progress in medical competence, professional team, and advanced medical equipment with high reputation both at home and abroad. The Urology Surgery at Zhongshan Hospital is a key discipline of National Ministry of Education, Project 211, and Project 985 Third Phase. The department is the Training Centre for specialist physicians of Ministry of Health and urinary endoscope treatment technology, a component of Fudan University Urology Surgery Research Institute, an initiative unit of Fudan University Organ Transplant Research Institute, and an attached institution of Shanghai Organ Transplant Key Laboratory. The department has 33 staff, including 8 full professors and 5 associate professors. The Urology Surgery Department is also one of the first to provide master and doctoral programmes, with 9 postgraduate supervisors.
Currently, the Urology Surgery Department consists of seven sub-special sections, namely urinary tract neoplasm, urinary calculus, prostate and urinary continence, adrenal gland surgery, renal transplantation, minimal invasive urology surgery, and andrology, and offers special, specialized disease, and specialist outpatient services. Treatment rooms include Urology Surgery Research Laboratory, Lithotripsy Room, Urodynamics Room, Urinary Endoscope Room, Male Sexual Function Examination and Diagnosis Room, and High Intensity Focused Ultrasound Neoplasm Treatment Room, etc. Annual outpatient and emergency visits exceed 120,000 and over 4600 patients are discharged from hospital every year. Over 4,000 operations are performed each year, of which 70% to 80% are major surgeries. More than 2,200 outpatient cystoscopic examinations, over 800 extracorporeal shock wave lithotripsies, and about 500 transrectal prostatic biopsies are conducted annually.
The Urology Surgery Department possesses many advanced medical equipments, including “Da Vinci S” Robot Surgical System, Digital Tablet Panoramic Urinary Examination X-ray Machine, ESWL, High Intensity Focused Ultrasound Neoplasm Treatment Machine, Radioactive Seeds Implantation in Prostate Cancer Treatment System, Generation 5 EMS, Infrared Spectroscopic Calculus Component Analyser, Urinary Dynamics Apparatus, Multi-functional Andrology Treatment Station, High-power Holmium Laser, and Urinary Ultrasonograph, etc. The department is also equipped with urinary endoscopes that include imported pyeloscope, flexible and rigid ureteroscope, flexible and rigid electron cystoscope, prostate vaporisation, plasma, laser resectoscope, electronic laparoscope, and other relative high-definition display systems. The Urology Surgery Research Laboratory has research equipments such as Luminex high-throughput liquid-phase analytic system, Miltenyi Biotec Magnetic-activated Cell-sorting System / Flow Cytometre Cell-sorting System, Automatic Gene Analyser, etc.
The whole team of the department will continue to carry on the tradition and develop more advantages, dedicating to building an urology surgery centre that is a national leader and international main player, with high medical level, distinctive specialties, strong research capabilities, multi-layered talent team, and wide influence.
A Systematic and Personalised Comprehensive System for Diagnosis and Treatment of Urinary System Tumors (Especially Renal Carcinoma and Prostate Cancer):The department treats more than 600 cases of renal carcinoma and over 400 cases of prostate cancer each year. We have established database and specimen bank of renal carcinoma and prostate cancer, and follow-up outpatient service for specialized diseases. Efforts have been made in studying highly challenging surgeries such as radical nephrectomy and nephron-sparing surgery, as well as increasing the excision rate by refining surgical skills. The department is also dedicated to prolonging the survival of patients with advanced renal carcinoma by adopting neoadjuvant therapy, targeted therapy, and high intensity focused ultrasound (HIFU) therapy. Different therapeutic methods are used to treat prostate cancer, focusing on minimally invasive treatment of early-stage prostate cancer, such as laparoscoperadical prostatectomy, robot-assisted radical prostatectomy, and radioactive seed implantation. The Urology Surgery Department has also proposed a new model that combines endocrine therapy with local therapy for treating mid-to-late stage prostate cancer. HIFU therapy plus radiation therapy for pelvic lymph nodes have been developed to enhance the general and disease-specific survival rate and improve the prognosis. Relevant achievements have won Shanghai Medical Science and Technology Award and Shanghai Outstanding Invention Award.
A Minimally Invasive Technology-Centered High-level Urinary Calculus Prevention and Treatment System:Our department has a whole set of urinary calculus clinical diagnosis, treatment and research equipment that comprises of rigid and flexible ureteroscopy, percutaneous nephroscope, extracorporeal shock wave lithotripsy (ESWL), the latest model of EMS lithoclast, holmium laser, C-arm machine, ultrasonic instrument, Infrared Spectroscopic Calculus Component Analyser and so on. The equipment is mainly used to optimize the treatment strategies and surgical skills for complex calculus of upper urinary tract (solitary urinary calculus, complete staghorn renal calculus, struvite stone, horseshoe renal calculus, urolithiasis in transplanted kidney, and senile and infantile renal calculus). We have also built a urinary calculus database. After the Sanlu Tainted Milk Incident had been exposed in 2008, Chief Physician Guo Jianming was appointed by the Ministry of Health as a member of the expert group and travelled to a hospital in Hebei Province several times to perform minimally invasive closed operations for dozens of babies who suffered from renal calculus and renal failure. The project saved many lives and benefited the society, and hence was awarded the silver prize of Shanghai Outstanding Invention Award and second place of the 5th Endos Award of Medical Science and Technology.
A Living Relative Donor-Featured, Immune Tolerance Induction-Centered High-Quality Renal Transplantation Diagnosis and Treatment System :Relative Renal Transplant is crucial to renal transplantation. From the year 2004, our department has developed our strength in laparoscopic surgery by providing diversified approaches of donor nephrectomy, from hand-assisted laparoscopy, laparoscopy, to da Vinci S-assisted laparoscopy, in order to minimize the physical pain of donors and ensure the quality of kidneys. In terms of clinical immune tolerance induction, our department emphasizes the combination of donor’s hematopoietic stem cell transplantation (HSCT) and renal transplantation, with the purpose of reducing the volume of immunosuppressant and improving long-term survival rate. The renal transplantation team led by Professor Zhu Tongyu is a leader in success rate of operations and long-term survival rates of patients and kidneys. Incidents such as “Being Saved by the Son’s Kidney” and “Love Under the Blue Sky: Operations for Charity” have been broadcasted on the media repeatedly and are widely acclaimed.